Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru
Abstract Objective Our study analyzes the cost-effectiveness of the COVID-19 vaccination campaigns in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. Methods Using a previously published SVEIR model, we analyzed the impact of a vaccination campaign (2021) from a national healthcare...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Online Access: | https://doi.org/10.1186/s12962-023-00430-2 |
| _version_ | 1797559435582767104 |
|---|---|
| author | Federico Augustovski Ariel Bardach Adrián Santoro Federico Rodriguez-Cairoli Alejandro López-Osornio Fernando Argento Maissa Havela Alejandro Blumenfeld Jamile Ballivian Germán Solioz Analía Capula Analía López Cintia Cejas William Savedoff Alfredo Palacios Adolfo Rubinstein Andrés Pichon-Riviere |
| author_facet | Federico Augustovski Ariel Bardach Adrián Santoro Federico Rodriguez-Cairoli Alejandro López-Osornio Fernando Argento Maissa Havela Alejandro Blumenfeld Jamile Ballivian Germán Solioz Analía Capula Analía López Cintia Cejas William Savedoff Alfredo Palacios Adolfo Rubinstein Andrés Pichon-Riviere |
| author_sort | Federico Augustovski |
| collection | DOAJ |
| description | Abstract Objective Our study analyzes the cost-effectiveness of the COVID-19 vaccination campaigns in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. Methods Using a previously published SVEIR model, we analyzed the impact of a vaccination campaign (2021) from a national healthcare perspective. The primary outcomes were quality adjusted life years (QALYs) lost and total costs. Other outcomes included COVID-19 cases, hospitalizations, deaths, and life years. We applied a discount rate of 3% for health outcomes. We modeled a realistic vaccination campaign in each country (the realistic country-specific campaign). Additionally, we assessed a standard campaign (similar, “typical“ for all countries), and an optimized campaign (similar in all countries with higher but plausible population coverage). One-way deterministic sensitivity analyses were performed. Findings Vaccination was health improving as well as cost-saving in almost all countries and scenarios. Our analysis shows that vaccination in this group of countries prevented 573,141 deaths (508,826 standard; 685,442 optimized) and gained 5.07 million QALYs (4.53 standard; 6.03 optimized). Despite the incremental costs of vaccination campaigns, they had a total net cost saving to the health system of US$16.29 billion (US$16.47 standard; US$18.58 optimized). The realistic (base case) vaccination campaign in Chile was the only scenario, which was not cost saving, but it was still highly cost-effective with an ICER of US$22 per QALY gained. Main findings were robust in the sensitivity analyses. Interpretation The COVID-19 vaccination campaign in seven Latin American and Caribbean countries -that comprise nearly 80% of the region- was beneficial for population health and was also cost-saving or highly cost-effective. |
| first_indexed | 2024-03-10T17:45:25Z |
| format | Article |
| id | doaj.art-e3e8ec0487054424b4159ccb027c9f8e |
| institution | Directory Open Access Journal |
| issn | 1478-7547 |
| language | English |
| last_indexed | 2024-03-10T17:45:25Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj.art-e3e8ec0487054424b4159ccb027c9f8e2023-11-20T09:33:15ZengBMCCost Effectiveness and Resource Allocation1478-75472023-04-0121111310.1186/s12962-023-00430-2Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and PeruFederico Augustovski0Ariel Bardach1Adrián Santoro2Federico Rodriguez-Cairoli3Alejandro López-Osornio4Fernando Argento5Maissa Havela6Alejandro Blumenfeld7Jamile Ballivian8Germán Solioz9Analía Capula10Analía López11Cintia Cejas12William Savedoff13Alfredo Palacios14Adolfo Rubinstein15Andrés Pichon-Riviere16Departamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicySocial InsightDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyCentro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyDepartamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department/ Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health PolicyAbstract Objective Our study analyzes the cost-effectiveness of the COVID-19 vaccination campaigns in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. Methods Using a previously published SVEIR model, we analyzed the impact of a vaccination campaign (2021) from a national healthcare perspective. The primary outcomes were quality adjusted life years (QALYs) lost and total costs. Other outcomes included COVID-19 cases, hospitalizations, deaths, and life years. We applied a discount rate of 3% for health outcomes. We modeled a realistic vaccination campaign in each country (the realistic country-specific campaign). Additionally, we assessed a standard campaign (similar, “typical“ for all countries), and an optimized campaign (similar in all countries with higher but plausible population coverage). One-way deterministic sensitivity analyses were performed. Findings Vaccination was health improving as well as cost-saving in almost all countries and scenarios. Our analysis shows that vaccination in this group of countries prevented 573,141 deaths (508,826 standard; 685,442 optimized) and gained 5.07 million QALYs (4.53 standard; 6.03 optimized). Despite the incremental costs of vaccination campaigns, they had a total net cost saving to the health system of US$16.29 billion (US$16.47 standard; US$18.58 optimized). The realistic (base case) vaccination campaign in Chile was the only scenario, which was not cost saving, but it was still highly cost-effective with an ICER of US$22 per QALY gained. Main findings were robust in the sensitivity analyses. Interpretation The COVID-19 vaccination campaign in seven Latin American and Caribbean countries -that comprise nearly 80% of the region- was beneficial for population health and was also cost-saving or highly cost-effective.https://doi.org/10.1186/s12962-023-00430-2 |
| spellingShingle | Federico Augustovski Ariel Bardach Adrián Santoro Federico Rodriguez-Cairoli Alejandro López-Osornio Fernando Argento Maissa Havela Alejandro Blumenfeld Jamile Ballivian Germán Solioz Analía Capula Analía López Cintia Cejas William Savedoff Alfredo Palacios Adolfo Rubinstein Andrés Pichon-Riviere Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru Cost Effectiveness and Resource Allocation |
| title | Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru |
| title_full | Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru |
| title_fullStr | Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru |
| title_full_unstemmed | Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru |
| title_short | Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru |
| title_sort | cost effectiveness of covid 19 vaccination in latin america and the caribbean an analysis in argentina brazil chile colombia costa rica mexico and peru |
| url | https://doi.org/10.1186/s12962-023-00430-2 |
| work_keys_str_mv | AT federicoaugustovski costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT arielbardach costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT adriansantoro costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT federicorodriguezcairoli costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT alejandrolopezosornio costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT fernandoargento costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT maissahavela costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT alejandroblumenfeld costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT jamileballivian costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT germansolioz costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT analiacapula costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT analialopez costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT cintiacejas costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT williamsavedoff costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT alfredopalacios costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT adolforubinstein costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu AT andrespichonriviere costeffectivenessofcovid19vaccinationinlatinamericaandthecaribbeanananalysisinargentinabrazilchilecolombiacostaricamexicoandperu |